← Leaderboards
Hugh William Alsop
Kinoxis Therapeutics Pty Ltd
$2,134,304
Attributed
$6,402,913
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2019–25$5M$3.8M$2.5M$1.3M$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,402,913 · 2
By mechanism
UH3$3,603,973 · 1
UG3$2,798,940 · 1
Top collaborators
- Michael Thomas Bowen4 shared
- Iain Stewart Mcgregor4 shared
Most similar at Kinoxis Therapeutics Pty Ltd
Same institution · by research overlap
- Michael Thomas Bowen$2,134,304
- Iain Stewart McGregor$2,134,304
Others in their field
Other Emerging Leaders on “Acute Symptom”
- Abraham Aizer Brody · New York University School Of Medicine$18,899,006
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
- Xinhua Li · Nano Terra, Inc.$12,600,767
- Daniel Sing-Kwong Tsze · Columbia University Health Sciences$10,143,894
- Ana-Maria Vranceanu · Massachusetts General Hospital$8,104,890
- Jeffrey Reich · Sparian Biosciences, Inc.$7,941,988
Research focus
Acute SymptomFunding OpportunitiesAnimal EfficacyAnimal ModelFormulationBrainCanis FamiliarisCertificationCessation Of LifeClinical DevelopmentClinical ResearchAmes AssayClinical TrialsComparativeDosageDosage FormsDoseDrug DiscoveryDrug KineticsDrug SynthesisEfficacy TestingFirearmsFirst-In-HumanGenotoxicity
Grant awards (4)
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.$450,505
UH3 · FY2025 · DA · contact PI
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.$1,004,351
UH3 · FY2024 · DA · contact PI
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.$2,149,117
UH3 · FY2023 · DA · contact PI
Advancing KNX100 for the treatment of opioid withdrawal: preclinical efficacy and toxicology, and a phase 1 clinical program.$2,798,940
UG3 · FY2019 · DA · contact PI